SEVRA trial of vaccine responses during adalimumab or rituximab treatment in rheumatoid arthritis

Open-label trial of adalimumab, rituximab, Hepatitis A virus vaccine, tetanus toxoid, Pneumo 23 and 3 more in rheumatoid arthritis (RA) (2 cohorts), sponsored by Philip Remans, MD,PhD, Division of Clinical Immunology and Rheumatology, Hans Schipper, MD, PhD, Department of Internal Medicin, Theo Out, PhD, laboratory of Medical Immunology, René Lutter, PhD, Department of Experimental immunology, Ruth klaasen, MD, Division of Clinical Immunology and Rheumatology, Danielle Gerlag, MD, Division of Clinical Immunology and Rheumatology, Paul P. Tak, MD, PhD, Professor of Medicine. Primary endpoints: Positive vaccine response rate before and after biologic therapy and Definition of vaccine response. Started May 2007; status: recruiting.